Smith & Nephew little boosted by rivals' reports of improving hip and knee sales
Johnson & Johnson said sales of hip and knee implants and other surgical devices rose 7.7% in the third quarter
Company
Smith & Nephew PLC
LON:SN.
Smith & Nephew develops advanced medical devices for healthcare professionals around the world
147 stories · page 3 of 8
Smith & Nephew's shares slump as profit margins squeezed
Revenue slipped 3.1% to US$1.29bn for the second quarter
Smith & Nephew revenues jump as elective procedure volumes rebound
Revenue growth was 4.1% in established markets compared to 1.6% reported
Smith & Nephew FY operating profits double; CEO to depart
"We finished 2021 with a solid fourth quarter, despite nearly a week less trading than in 2020 and the impact of Omicron," said CEO Roland Diggelmann
Smith & Nephew sees full-year performance at low end of guidance on impact from Delta variant and supply chain issues
Orthopaedics revenue fell 5.9% in the third quarter
Smith & Nephew shares represent a “rare value opportunity”, according to a leading investment bank
The number crunchers at Credit Suisse rate the stock 'outperform'
Smith & Nephew growth drivers underappreciated, says Credit Suisse
The bank's analysts said that investors “underestimate the combined power of recently-acquired growth drivers" and that they expected the medical equipment group’s stock to “reverse its material underperformance over the past 12 months”
Smith & Nephew sees the light at the end of the tunnel
The firm is benefitting from vaccine rollouts and healthcare systems reopening to non-urgent surgery
Smith & Nephew suffers nasty fall
The company said the COVID-19 pandemic continued to have an impact on trading performance as hip and knee replacement operations the world over were delayed
Smith & Nephew sales fall faster as surgeries postponded due to coronavirus
Underlying sales fell around 7% in the fourth quarter, compared to 4.2% in the third and 18.7% in the first half
Smith & Nephew returns to growth in US division but gives no guidance
The US was up 1% on an underlying basis but was offset by a 6% decline in other established markets
Smith & Nephew posts quarterly revenue recovery
Third-quarter revenue only dipped 4% compared to a 29% decline in the previous three months
Smith & Nephew stumbles to loss after pandemic hits surgeries
The interim dividend of 14.4 cents per share is the same as was declared a year ago
Smith & Nephew sales decline eases in June as more elective surgeries begin
Hip and knee reconstruction, sports injuries, and ENT businesses were hit hardest by the impact of the pandemic
Smith & Nephew monthly revenue nearly halves as most markets stop non-emergency surgery
Procedures are starting to return in some countries, including the US, while China has shown improved trading
Smith & Nephew weak as Citigroup downgrades to ‘neutral’ citing impact of coronavirus pandemic
The US investment bank also cut its earnings per share estimates for the FTSE 100-listed firm by 15%-22% and reduced its target price to 1,700p from 2,250p
Smith & Nephew appoints new chief financial officer
Anne-Francoise Nesmes is currently holding the same role at leisure parks operator Merlin Entertainments
Smith & Nephew drops guidance as surgical procedures stop amid pandemic
Underlying revenue growth in the quarter to March is expected to drop 8% on 2019
Analysts mull Smith & Nephew's big coronavirus assumptions
“The near term downside risk…is that either China remains challenged for longer, or COVID-19 spreads more widely,” said analysts at JPMorgan Cazenove
Smith & Nephew's 2019 revenue growth at the top end of the range
The medical devices maker had guided towards revenue growth of 3.5-4.5%; it achieved growth of 4.4%